UNSPSC 51143502: Carbidopa/levodopa

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN500. This VA Drug Class (CN500) classifies this compound as belonging to the group ANTIPARKINSON AGENTS.

UNSPSC 51143502 Carbidopa/levodopa is a Commodity code that in practice encompasses a much broader range of pharmaceutical procurement than the code name alone suggests. State and local governments solicit under this code for generic multi-source pharmaceuticals, over-the-counter products, and pharmaceutical program administration through cooperative purchasing vehicles and direct contracting mechanisms. The issuing bodies include state health departments, county health agencies, and multistate cooperative purchasing alliances. The scope reflects institutional healthcare needs — bulk supply agreements for pharmaceutical distribution through authorized wholesalers, direct-to-manufacturer contracting to improve cost management and fulfillment efficiency, and community health initiatives requiring quarterly deliveries of specific pharmaceutical products.

Activity appears concentrated in the Upper Midwest and Southeast. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with authorized wholesaler distribution and contract effectiveness July 1, 2026. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, requiring electronic bidding and including a three-month probationary termination clause. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs to support pharmacy benefit management outside traditional PBM and GPO channels. Cooperative purchasing vehicles and multistate alliances structure much of the recent procurement activity, with requirements for cGMP certification, DSCSA compliance, multiple pricing format options, and authorized wholesaler relationships.